untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:24:21Z</responseDate>
<request identifier=oai:HAL:hal-01294307v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01294307v1</identifier>
<datestamp>2018-01-11</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:CNRS</setSpec>
<setSpec>collection:CIMI</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:U835</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:CIC</setSpec>
<setSpec>collection:CIC203</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UPMC_POLE_4</setSpec>
<setSpec>collection:IRSET-EHESP</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014</title>
<creator>Henry, Benoît</creator>
<creator>Revest, Matthieu</creator>
<creator>Dournon, Nathalie</creator>
<creator>Epelboin, Loïc</creator>
<creator>Mellon, Guillaume</creator>
<creator>Bellaud, Guillaume</creator>
<creator>Mordant, Pierre</creator>
<creator>Le Dû, Damien</creator>
<creator>Véziris, Nicolas</creator>
<creator>Bernard, Christine</creator>
<creator>Morel, Sébastien</creator>
<creator>Jauréguiberry, Stéphane</creator>
<creator>Michelet, Christian</creator>
<creator>Bricaire, François</creator>
<creator>Tattevin, Pierre</creator>
<creator>Caumes, Éric</creator>
<contributor>Université Pierre et Marie Curie - Paris 6 (UPMC)</contributor>
<contributor>CHU Pitié-Salpêtrière [APHP]</contributor>
<contributor>CHU Pontchaillou [Rennes]</contributor>
<contributor>Hôpital Européen Georges Pompidou [APHP] (HEGP)</contributor>
<contributor>CHU Bligny</contributor>
<contributor>Centre d'Immunologie et de Maladies Infectieuses (CIMI) ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS)</contributor>
<contributor>Centre National de Référence de Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Fonction, structure et inactivation d'ARN bactériens ; Université de Rennes 1 (UR1) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Centre d'Investigation Clinique [Rennes] (CIC) ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<description>International audience</description>
<source>ISSN: 1080-6040</source>
<source>EISSN: 1080-6059</source>
<source>Emerging Infectious Diseases</source>
<publisher>Centers for Disease Control and Prevention</publisher>
<identifier>hal-01294307</identifier>
<identifier>http://hal.upmc.fr/hal-01294307</identifier>
<identifier>http://hal.upmc.fr/hal-01294307/document</identifier>
<identifier>http://hal.upmc.fr/hal-01294307/file/15-1130.pdf</identifier>
<source>http://hal.upmc.fr/hal-01294307</source>
<source>Emerging Infectious Diseases, Centers for Disease Control and Prevention, 2016, 22 (3), pp.518-521. 〈10.3201/eid2203.151130〉</source>
<identifier>DOI : 10.3201/eid2203.151130</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.3201/eid2203.151130</relation>
<identifier>PUBMED : 26891089</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/26891089</relation>
<language>en</language>
<subject lang=en>multidrug-resistant tuberculosis</subject>
<subject lang=en>MDR TB</subject>
<subject lang=en>antimicrobial resistance</subject>
<subject lang=en>outcome</subject>
<subject lang=en>XDR TB</subject>
<subject lang=en>TB</subject>
<subject lang=en>tuberculosis</subject>
<subject lang=en>extensively drug-resistant tuberculosis</subject>
<subject lang=en>France</subject>
<subject lang=en>thoracic surgery</subject>
<subject lang=en>bedaquiline</subject>
<subject lang=en>bacteria</subject>
<subject lang=en>tuberculosis and other mycobacteria</subject>
<subject>[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>We report 20 cases of extensively drug-resistant tuberculosis managed in France. Treatment was individualized and included bedaquiline and linezolid for most patients and surgery in 8 patients. At last follow-up (22 months), 19 patients had achieved conversion from positive to negative on culture testing. These promising results of comprehensive management obtained in a small series deserve confirmation.</description>
<date>2016</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
